PENTA 20 (Odyssey)

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing 14 to <25kg on film-coated dolutegravir 25mg tablets

14 Oct, 2018

Authors: Bollen P, Turkova A, Hilda Mujuru H, et al. The ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, 20-21st July 2018. Poster Number 22
Read More

ODYSSEY: design, current status, and baseline characteristics

14 Oct, 2018

Authors: Moore CL,  Kekitinwa A, Kaudha E, et al; the ODYSSEY Trial Team Published in: 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018. Poster Number 34
Read More

“I failed to take them as I should and now I’m scared”: how can we support adolescents’ adherence on second line HIV treatment

09 Oct, 2018

Authors: Bernays S, Namukwaya S, Mupambireyi Z, Nanduudu A, Mujuru H, Turkova A, Gibb DM, Seeley J, and the ODYSSEY Trial Team. Published in: 10th International Workshop on HIV Pediatrics,…
Read More

Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing ≥25kg after switching to 50mg film-coated dolutegravir tablets in the ODYSSEY trial

14 Sep, 2018

Authors: Turkova A, Bollen P, Kaudha E, et al. The ODYSSEY Trial Team Published in: Oral Presentation at 10th International Workshop on HIV Pediatrics, Amsterdam, July 20-21st, 2018
Read More
1 2 3